Galactosemia and Fructosemia

Galactosemia: Three Enzymatic Forms and Their Mechanisms

• Classic galactosemia (galactose-1-phosphate uridyltransferase [GALT] deficiency) represents the most common and severe form (>90% of cases). In normal metabolism, dietary galactose (from lactose in milk and dairy products) is phosphorylated by galactokinase to galactose-1-phosphate, which is then converted by GALT to UDP-galactose and glucose-1-phosphate. When GALT activity is absent or severely reduced (<10% of normal), galactose-1-phosphate accumulates to toxic concentrations in liver, kidney, lens, and brain. This accumulation drives three pathological mechanisms: (1) osmotic stress and cellular dehydration from the phosphorylated compound's impermeability across cell membranes, leading to water influx and cellular swelling; (2) depletion of inorganic phosphate (Pi) pools through sequestration in galactose-1-phosphate, reducing ATP synthesis and impairing energy-dependent cellular functions; and (3) formation of galactitol through the polyol pathway when accumulated galactose is reduced by aldose reductase. Galactitol accumulation in the lens causes osmotic swelling, lens fiber disruption, and nuclear cataracts—often the earliest clinical sign. The phosphate depletion mechanism is particularly critical in hepatocytes, causing mitochondrial dysfunction, impaired protein synthesis, and progressive hepatic necrosis. Additionally, UDP-galactose deficiency (the product normally made by GALT) impairs synthesis of galactose-containing glycoproteins and glycolipids, disrupting myelin formation and contributing to intellectual disability if untreated during the critical myelination period (first 2-3 years of life).

• Galactokinase deficiency (rare, ~1-2% of galactosemia cases) results in failure to phosphorylate galactose to galactose-1-phosphate. Consequently, galactose accumulates in blood and is reduced via aldose reductase to galactitol, which accumulates in tissues (particularly the lens, kidney, and nerve). The key pathophysiological difference from classic galactosemia is the absence of galactose-1-phosphate accumulation, meaning there is no phosphate depletion or hepatotoxicity. Therefore, the clinical presentation is limited almost exclusively to infantile cataracts from galactitol accumulation and osmotic stress in the lens. This form has a much more benign prognosis—intellectual disability and liver disease do not develop. Pseudotumor cerebri (benign intracranial hypertension) has been reported in some cases.

• UDP-galactose-4-epimerase (GALE) deficiency exists in two forms: (a) peripheral form (benign) affecting only red blood cells and white blood cells with preserved enzyme activity in liver and other tissues—clinically asymptomatic despite elevated blood galactose; and (b) generalized form (very rare) with systemic enzyme deficiency causing a clinical picture intermediate between GALT deficiency and galactokinase deficiency. The peripheral form is often discovered incidentally on newborn screening and requires no treatment.

Fructosemia Pathophysiology

• Hereditary fructose intolerance (HFI; aldolase B deficiency) is the most clinically significant form. When dietary fructose is consumed, it is normally phosphorylated by fructokinase to fructose-1-phosphate in the liver. In HFI, aldolase B is absent or severely deficient, so fructose-1-phosphate accumulates to toxic levels. This causes: (1) massive sequestration of inorganic phosphate in fructose-1-phosphate, severely depleting the Pi pool required for ATP synthesis—this mechanism is even more dramatic than in classic galactosemia because fructokinase has very high activity and fructose-1-phosphate accumulates more rapidly; (2) inhibition of gluconeogenesis (aldolase A is also inhibited) and glycogenolysis (phosphorylase is inhibited by Pi depletion), causing acute severe hypoglycemia within minutes to hours after fructose ingestion; (3) ATP depletion in hepatocytes leading to acute hepatocellular necrosis with cholestasis, elevated transaminases, and hyperbilirubinemia; (4) inhibition of fructose-1,6-bisphosphatase and other gluconeogenic enzymes, perpetuating hypoglycemia; and (5) inhibition of protein synthesis, contributing to acute liver injury. The metabolic derangement is rapid and severe—symptoms typically appear within 20-30 minutes of fructose ingestion (or sucrose, which contains fructose). Chronic exposure leads to hepatic cirrhosis, renal tubular dysfunction (from accumulated fructose-1-phosphate in renal cells), and growth retardation.

• Essential fructosemia (fructokinase deficiency) is benign because although fructose accumulates in blood and is excreted in urine (causing fructosuria), there is no formation of the toxic fructose-1-phosphate intermediate. These patients are typically asymptomatic, and the condition is discovered incidentally on newborn screening or when fructose is identified in the urine.

• Triose kinase deficiency is exceptionally rare with unknown clinical significance.

Tissue-Specific Pathophysiology and Organ Damage

• Mitochondrial oxidative phosphorylation and ATP production
• Hepatic protein synthesis, including clotting factors (explaining coagulopathy)
• Detoxification pathways and bile acid synthesis
• Maintenance of the blood-brain barrier

Classic Galactosemia (GALT Deficiency)

• **Mutations in the GALT gene (chromosome 9p13)**: Over 200 different mutations have been identified, including point mutations, deletions, and insertions. The GALT gene encodes galactose-1-phosphate uridyltransferase. Common mutations vary by ethnicity—the Q188R mutation is prevalent in Caucasian populations, while L195P is common in African populations and IVS2+1G>A in Asian populations. Homozygosity or compound heterozygosity for severe loss-of-function mutations results in classic galactosemia. Newborn screening has identified an important variant: individuals with neonatal screening-detected galactosemia (NSDG) or Duarte galactosemia who have intermediate enzyme levels (10-50% of normal) from specific mutations (particularly N314D)—these patients typically have a much milder course than classic galactosemia, though long-term sequelae remain possible.

• Dietary exposure to lactose: Galactosemia only manifests clinically when infants are fed milk or dairy products containing lactose. Exclusively breastfed or formula-fed infants will present with symptoms within the first 1-2 weeks of life when milk feeding begins.

Galactokinase Deficiency

• **Mutations in the GALK1 gene (chromosome 17q24)**: Loss-of-function mutations. This is a very rare cause of elevated blood galactose and is distinguished from other forms by a specific pattern on newborn screening (elevated galactose but normal galactose-1-phosphate levels in red blood cells).

UDP-Galactose-4-Epimerase Deficiency

• **Mutations in the GALE gene (chromosome 1p36)**: The peripheral (benign) form arises from mutations allowing residual enzyme activity in liver and other tissues while completely losing activity in red and white blood cells. The generalized form results from mutations causing systemic enzyme deficiency.

Hereditary Fructose Intolerance (Aldolase B Deficiency)

• **Mutations in the ALDOB gene (chromosome 9q22.3): The aldolase B gene encodes the liver isoform of aldolase. More than 25 different mutations have been identified, including A149P (most common in Northern Europe), A175G (common in Southern Europe), and N334K** (found in various populations). Affected individuals are homozygous or compound heterozygous for these loss-of-function mutations. The severity of clinical manifestations correlates somewhat with residual aldolase B activity—patients with complete absence have the most severe presentations.

• Dietary exposure to fructose and sucrose: HFI manifests only when infants consume fruits, honey, table sugar (sucrose), or foods sweetened with fructose or sucrose. Some patients remain asymptomatic if they avoid these foods completely, but accidental exposure causes acute, severe symptoms.

• Risk factors for diagnosis: A family history of fructose intolerance, failure to thrive after introduction of fruits or sweetened foods, or neonatal cholestasis triggered by fruit or sucrose introduction should raise suspicion.

Risk Factors Increasing Severity or Clinical Manifestations

• Early and prolonged lactose/fructose exposure: Continued feeding with lactose-containing formula or breast milk in undiagnosed galactosemia, or repeated fructose exposure in HFI, worsens liver and neurological damage.
• Delayed diagnosis: Infants not identified through newborn screening programs and not started on restricted diets until later in infancy have worse long-term neurological and hepatic outcomes.
• Nutritional status and intercurrent illness: Metabolic stress from infection or inadequate nutrition may precipitate acute decompensation in undiagnosed cases.

Classic Galactosemia: The Presentation Timeline

• Earliest sign—infantile cataracts (2-4 weeks of age): The cataract is often the first clinical manifestation, appearing as a "oil drop" opacity in the nucleus of the lens in the first weeks of life. This occurs because galactitol accumulates rapidly in the lens, causing osmotic swelling and disruption of lens transparency. The cataract may be unilateral or bilateral and can progress to complete opacity within days if lactose feeding continues. Importantly, cataracts are reversible if caught very early (within the first 1-2 weeks of galactitol accumulation) because galactitol can be mobilized from the lens; however, after several weeks, structural lens changes become irreversible even with dietary restriction.

• Jaundice and hepatomegaly (first 1-2 weeks): Even before the cataract becomes obvious, affected newborns may present with unconjugated and conjugated hyperbilirubinemia (from hepatic dysfunction), hepatomegaly, and clinical jaundice. The bilirubin elevation typically appears by 3-5 days of age but may be attributed to "physiologic jaundice" or hemolysis if not specifically evaluated. Hepatomegaly is prominent and may reach several centimeters below the costal margin.

• Acute liver dysfunction (first 2 weeks onward): Progressive hepatic disease manifests as elevated transaminases (ALT, AST), elevated direct (conjugated) bilirubin, coagulopathy (elevated PT/INR, reflecting impaired synthesis of vitamin K–dependent clotting factors), hypoglycemia, and in severe cases, acute liver failure with encephalopathy. Laboratory studies show markedly elevated transaminases (often ALT and AST >500 IU/L), conjugated hyperbilirubinemia, and low albumin. Lactic acidosis may develop from impaired hepatic metabolism and mitochondrial dysfunction. Ascites may develop, and the liver becomes firm and cirrhotic-appearing on ultrasound.

• Renal tubular dysfunction: Accumulation of galactose-1-phosphate in renal cells causes generalized aminoaciduria (loss of amino acids in urine despite normal serum levels), fanconi syndrome features (renal tubular acidosis, phosphaturia), and in some cases, nephrotic-range proteinuria. Renal function may be severely impaired, though complete renal failure is uncommon if the disease is caught early.

• Intellectual disability (if untreated beyond infancy): Infants not identified and treated before 3 months of age develop progressively worsening developmental delay. The delay becomes apparent in the first 6-12 months with failure to achieve developmental milestones. If untreated through the critical myelination period (first 2-3 years), severe intellectual disability, cerebral palsy, and hypotonia develop. These neurological changes are largely irreversible even after dietary restriction is initiated. MRI may show delayed myelination, periventricular white matter changes, and cerebellar atrophy.

• Speech and language disorder: Affected children develop dysarthria and language delay. Many children remain nonspeaking or have severely limited verbal communication.

• Behavioral and psychiatric complications: Beyond the newborn period, untreated or inadequately treated patients develop behavioral problems, autism spectrum disorder features, attention-deficit/hyperactivity disorder (ADHD), and anxiety disorders.

Galactokinase Deficiency: A Benign Variant

• Infantile cataracts only (within first weeks of life): The cataracts develop similarly to classic galactosemia from galactitol accumulation. However, unlike classic galactosemia, these cataracts may be reversible with galactose restriction, and the prognosis is generally good.
• Pseudotumor cerebri (benign intracranial hypertension): Some cases present with headache, papilledema, and elevated intracranial pressure

Buzzwords that give away the diagnosis

• "Oil-droplet" nuclear cataract in a jaundiced neonate with hepatomegaly after milk feeding = classic galactosemia (GALT deficiency). Cataracts alone in an otherwise well infant = galactokinase deficiency (galactitol only, no galactose-1-phosphate, so no liver or brain disease).
• ***E. coli* neonatal sepsis** is the single association examiners test most: galactose-1-phosphate accumulation impairs neutrophil bactericidal function, so any neonate with gram-negative sepsis plus jaundice, hepatomegaly, and hypoglycemia should prompt evaluation for classic galactosemia.
• Hereditary fructose intolerance (aldolase B) declares itself at weaning — when fruit, juice, or sucrose-containing formula is introduced — with vomiting, hypoglycemia, and liver dysfunction. Older undiagnosed children show aversion to sweets and notably few dental caries.

Single best next step

• Stop the offending sugar immediately and give IV dextrose. For suspected galactosemia, remove all lactose (breast milk and cow's-milk formula) and switch to a soy-based or elemental formula; for suspected HFI, eliminate fructose, sucrose, and sorbitol. Do not wait for confirmatory testing — the ACMG ACT sheets for abnormal newborn screening emphasize same-day dietary intervention.
• Confirmation: classic galactosemia by erythrocyte GALT enzyme activity (plus genotyping); HFI by ***ALDOB* gene sequencing** — an oral/IV fructose challenge is diagnostic but can precipitate severe hypoglycemia and is not first-line.

Screening and labs

• Galactosemia is on the Recommended Uniform Screening Panel (HRSA/ACHDNC) and is screened in all US states; HFI is not screened, so it is a clinical diagnosis.
• Urine reducing substances positive with a negative glucose-oxidase dipstick = a non-glucose reducing sugar (galactose or fructose). Classic distractor: calling this glucosuria/diabetes.
• HFI labs: hypoglycemia, hypophosphatemia, hyperuricemia, lactic acidosis, and transaminitis — all traceable to phosphate trapping in fructose-1-phosphate.

Distractors to avoid

• Essential fructosuria (fructokinase) and peripheral GALE deficiency are benign incidental findings requiring no treatment.
• Lactase deficiency causes osmotic diarrhea and flatus, never cataracts, liver failure, or sepsis.
• Even with perfect dietary compliance, classic galactosemia carries primary ovarian insufficiency and speech/learning deficits — the diet prevents acute crisis, not all long-term sequelae.